Literature DB >> 10471625

Cytokines IL-1beta, IL-6, and TNF-alpha enhance in vitro growth of bacteria.

G U Meduri1, S Kanangat, J Stefan, E Tolley, D Schaberg.   

Abstract

We have previously reported that in acute respiratory distress syndrome (ARDS), nonsurvivors have persistent elevation in pulmonary and circulating proinflammatory cytokine levels over time and a high rate of nosocomial infections antemortem. In these patients, none of the proven or suspected nosocomial infections caused a transient or sustained increase in plasma proinflammatory cytokine levels above preinfection values. We hypothesized that cytokines secreted by the host during ARDS may favor the growth of bacteria. We conducted an in vitro study of the growth of three bacteria clinically relevant in nosocomial infections, evaluating their in vitro response to various concentrations of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, and IL-6. We found that all three bacterial species showed concentration-dependent growth enhancement when incubated with one or more tested cytokines and that blockade by specific neutralizing cytokine MoAb significantly inhibited cytokine-induced growth. When compared with control, the 6-h growth response (cfu/ml) was maximal with IL-1beta at 1,000 pg for Staphylococcus aureus (36 +/- 16 versus 377 +/- 16; p = 0.0001) and Acinetobacter spp. (317 +/- 1,147 versus 1,124 +/- 147; p = 0.002) and with IL-6 at 1,000 pg for Pseudomonas aeruginosa (99 +/- 50 versus 509 +/- 50; p = 0.009). The effects of cytokines were seen only with fresh isolates and were lost with passage in vitro on bacteriologic medium without added cytokines. In this study we provide additional evidence for a newly described pathogenetic mechanism for bacterial proliferation in the presence of exaggerated and protracted inflammation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471625     DOI: 10.1164/ajrccm.160.3.9807080

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  41 in total

1.  Candida colonization in ventilated ICU patients: no longer a bystander!

Authors:  Jean-Damien Ricard; Damien Roux
Journal:  Intensive Care Med       Date:  2012-06-15       Impact factor: 17.440

Review 2.  The microbiome and critical illness.

Authors:  Robert P Dickson
Journal:  Lancet Respir Med       Date:  2015-12-12       Impact factor: 30.700

3.  Topical p38 MAPK inhibition reduces bacterial growth in an in vivo burn wound model.

Authors:  Kyros Ipaktchi; Aladdein Mattar; Andreas D Niederbichler; Laszlo M Hoesel; Sabrina Vollmannshauser; Mark R Hemmila; Rebecca M Minter; Grace L Su; Stewart C Wang; Saman Arbabi
Journal:  Surgery       Date:  2007-07       Impact factor: 3.982

Review 4.  Acute lower respiratory tract infection.

Authors:  Joseph P Mizgerd
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

Review 5.  [Classification of prosthetic loosening and determination of wear particles].

Authors:  M Otto
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

6.  Effects of methylprednisolone on intracellular bacterial growth.

Authors:  G U Meduri; S Kanangat; M Bronze; D R Patterson; C U Meduri; C Pak; E A Tolley; D R Schaberg
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

7.  Effects of cytokines and endotoxin on the intracellular growth of bacteria.

Authors:  S Kanangat; G U Meduri; E A Tolley; D R Patterson; C U Meduri; C Pak; J P Griffin; M S Bronze; D R Schaberg
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

8.  The fermentation product 2,3-butanediol alters P. aeruginosa clearance, cytokine response and the lung microbiome.

Authors:  Mytien Nguyen; Anurag Sharma; Wenzhu Wu; Rika Gomi; Biin Sung; Denina Hospodsky; Largus T Angenent; Stefan Worgall
Journal:  ISME J       Date:  2016-05-14       Impact factor: 10.302

9.  The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury.

Authors:  Hiroyuki Seki; Koichi Fukunaga; Makoto Arita; Hiroyuki Arai; Hiroki Nakanishi; Ryo Taguchi; Taku Miyasho; Rina Takamiya; Koichiro Asano; Akitoshi Ishizaka; Junzo Takeda; Bruce D Levy
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

Review 10.  Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application.

Authors:  George Hajishengallis; Evlambia Hajishengallis; Tetsuhiro Kajikawa; Baomei Wang; Despina Yancopoulou; Daniel Ricklin; John D Lambris
Journal:  Semin Immunol       Date:  2016-03-24       Impact factor: 11.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.